{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T18:01:40Z","timestamp":1726509700194},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.semnephrol.2005.05.005","type":"journal-article","created":{"date-parts":[[2005,11,21]],"date-time":"2005-11-21T20:24:29Z","timestamp":1132604669000},"page":"372-378","source":"Crossref","is-referenced-by-count":14,"title":["Heart Disease in Diabetic Patients"],"prefix":"10.1016","volume":"25","author":[{"given":"Robert D.","family":"Toto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2005.05.005_bib1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/ki.1992.114","article-title":"Eight to nine year mortality in known non-insulin dependent diabetics and controls","volume":"41","author":"Damsgaard","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib2","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1001\/archinte.164.17.1917","article-title":"Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes","volume":"164","author":"Klein","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/BF00281993","article-title":"The impact of proteinuria on the relative mortality in patients with type I diabetes mellitus","volume":"28","author":"Borch-Johnsen","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-4943(99)00031-X","article-title":"Coronary heart disease, type 2 diabetes mellitus and cardiovascular disease risk factors","volume":"29","author":"Giansanti","year":"1999","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib5","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1001\/archinte.164.13.1422","article-title":"The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death","volume":"164","author":"Almdal","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1464-5491.2004.01115.x","article-title":"WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes","volume":"21","author":"Marchesini","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib7","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinte.164.16.1737","article-title":"Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart","volume":"164","author":"Lim","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib9","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.mcna.2004.04.008","article-title":"Ischemic heart disease and congestive heart failure in diabetic patients","volume":"88","author":"Wilson Tang","year":"2004","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/oxfordjournals.eurheartj.a062516","article-title":"Left ventricular diastolic function in young long-term type 1 (insulin-dependent) diabetic men during exercise assessed by digitized echocardiography","volume":"9","author":"Danielsen","year":"1988","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib11","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/0735-1097(90)92818-M","article-title":"Myocardial mechanics in young adult patients with diabetes mellitus","volume":"15","author":"Borow","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/00005344-198409000-00021","article-title":"Is tissue converting enzyme inhibitor a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneous hypertensive rats","volume":"6","author":"Unger","year":"1984","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1388-1981(02)00342-6","article-title":"Lipoapoptosis","volume":"1585","author":"Unger","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib14","first-page":"H1225","article-title":"Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in type 2 diabetic patients","volume":"287","author":"Monti","year":"2004","journal-title":"Am J Physiol"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa013410","article-title":"Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes","volume":"347","author":"Lurbe","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib16","doi-asserted-by":"crossref","first-page":"700","DOI":"10.7326\/0003-4819-140-9-200405040-00009","article-title":"Coronary vasomotor abnormalities in insulin-resistant individuals","volume":"140","author":"Quinones","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11906-004-0072-y","article-title":"Diabetes, hypertension, and cardiovascular derangements","volume":"6","author":"El Atat","year":"2004","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-139-11-200312020-00008","article-title":"Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy","volume":"139","author":"Wachtell","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-133-2-200007180-00007","article-title":"Nontraditional risk factors for coronary heart disease incidence among persons with diabetes","volume":"133","author":"Saito","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib21","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1097\/01.ASN.0000018409.45834.FA","article-title":"Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals","volume":"13","author":"McClellan","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000078698","article-title":"The interaction between heart failure, renal failure and anemia\u2014the cardio-renal anemia syndrome","volume":"22","author":"Silverberg","year":"2004","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib23","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0735-1097(00)00613-6","article-title":"The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations","volume":"35","author":"Silverberg","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/ndt\/14.2.292","article-title":"Anaemia in the patient with renal insufficiency","volume":"14","author":"Levin","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl","key":"10.1016\/j.semnephrol.2005.05.005_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1523-1755.61.s80.7.x","article-title":"Anemia and left ventricular hypertrophy in chronic kidney disease populations","volume":"61","author":"Levin","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib26","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1681\/ASN.V12122759","article-title":"Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis","volume":"12","author":"London","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000170174","article-title":"Pathophysiology of left ventricular hypertrophy in dialysis patients","volume":"12","author":"London","year":"1994","journal-title":"Blood Purif"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ki.1987.94","article-title":"Uremic cardiomyopathy","volume":"31","author":"London","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib29","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1001\/archinte.159.22.2661","article-title":"Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels","volume":"159","author":"Haffner","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-2007-979948","article-title":"Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors","volume":"27","author":"Kazumi","year":"1995","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study: Cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib32","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2013Lipid Lowering Arm (ASCOT-LLA)","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36)","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib36","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib39","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1046\/j.1523-1755.1999.07158.x","article-title":"Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis","volume":"71","author":"Wanner","year":"1999","journal-title":"Kidney Int Suppl"},{"issue":"suppl","key":"10.1016\/j.semnephrol.2005.05.005_bib40","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","volume":"63","author":"Baigent","year":"2003","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.semnephrol.2005.05.005_bib41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ahj.2004.09.047","article-title":"Rationale\u2014Trial to reduce cardiovascular events with Aranesp Therapy (TREAT)","volume":"149","author":"Mix","year":"2005","journal-title":"AM Heart J"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib42","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1523-1755.1998.00055.x","article-title":"Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy","volume":"54","author":"Smith","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib44","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib46","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"year":"1994","author":"Raskin","series-title":"Diabetes control and complications trial","key":"10.1016\/j.semnephrol.2005.05.005_bib47"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib48","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib50","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.2337\/diacare.26.2007.S33","article-title":"Standards of medical care for patients with diabetes mellitus","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib52","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1097\/00004872-199312050-00074","article-title":"Association between smoking and micro-albuminuria in hypertensive patients with type 2 diabetes mellitus","volume":"11","author":"Corradi","year":"1993","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib53","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/bmj.314.7083.783","article-title":"Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus","volume":"314","author":"Gall","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib54","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2337\/diacare.26.3.911","article-title":"Smoking and progression of diabetic nephropathy in type 1 diabetes","volume":"26","author":"Hovind","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2005.05.005_bib55","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2337\/diacare.17.2.126","article-title":"Smoking is associated with progression of diabetic nephropathy","volume":"17","author":"Sawicki","year":"1994","journal-title":"Diabetes Care"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929505001002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929505001002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T03:25:58Z","timestamp":1626751558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929505001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0270929505001002"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2005.05.005","relation":{},"ISSN":["0270-9295"],"issn-type":[{"type":"print","value":"0270-9295"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}